Phase III Study Showed Two Years Of ACTEMRA(R) (tocilizumab) Inhibited Progression Of Joint Damage And Improved Disease Remission

Podiatry Arena Phase III Study Showed Two Years Of ACTEMRA(R) (tocilizumab) Inhibited Progression Of Joint Damage And Improved Disease Remission

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Phase III Study Showed Two Years Of ACTEMRA(R) (tocilizumab) Inhibited Progression Of Joint Damage And Improved Disease Remission

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

20th October 2009, 04:40 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,128

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 19 Times in 19 Posts

Phase III Study Showed Two Years Of ACTEMRA(R) (tocilizumab) Inhibited Progression Of Joint Damage And Improved Disease Remission

Podiatry Arena members do not see these ads

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Two-Year Data Reinforce Effect Of ACTEMRA(R) (tocilizumab) In Inhibiting Progression Of Joint Damage And Improving Physical Function In Arthritis	RSSFeedBot	Latest Rheumatology News	0	26th May 2009 04:20 AM
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis	RSSFeedBot	Latest Rheumatology News	0	27th December 2008 05:21 AM
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)	RSSFeedBot	Latest Rheumatology News	0	26th December 2008 06:30 AM
Cimzia(R) Study Shows Rapid Reduction Of Symptoms And Inhibition Of Joint Damage Progression In RA	RSSFeedBot	Latest Rheumatology News	0	31st October 2008 06:23 AM
ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting	RSSFeedBot	Latest Rheumatology News	0	21st October 2008 04:10 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 12:48 PM.

User Name		Remember Me?
Password